Patents by Inventor D. Scott Edwards

D. Scott Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
    Patent number: 11858900
    Abstract: The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: January 2, 2024
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: D. Scott Edwards, Ben C. Askew, Takeru Furuya
  • Fluorinated integrin antagonists
    Patent number: 11685737
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: June 27, 2023
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS
    Publication number: 20230129394
    Abstract: The present application relates to use of fluorinated compounds of Formula (I) in treating or preventing a viral infection or a condition or symptom associated with the viral infection.
    Type: Application
    Filed: November 8, 2022
    Publication date: April 27, 2023
    Inventor: D. Scott Edwards
  • Fluorinated 4-(substituted amino)phenyl carbamate derivatives
    Patent number: 10676437
    Abstract: The application relates to 4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 9, 2020
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Takeru Furuya, Ben C. Askew, D. Scott Edwards
  • Fluorinated integrin antagonists
    Patent number: 10106537
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 23, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated benzofuran derivatives
    Patent number: 9895340
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 20, 2018
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Fluorinated integrin antagonists
    Patent number: 9717729
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 1, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated benzofuran derivatives
    Patent number: 9624189
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 18, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20170071939
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 16, 2017
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
    Patent number: 9572801
    Abstract: The present application relates to use of compounds of formula I for treating or preventing a fibrosis.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: February 21, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, D. Scott Edwards
  • Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
    Patent number: 9556114
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 31, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards, Ajay Purohit
  • Fluorinated integrin antagonists
    Patent number: 9518053
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: December 13, 2016
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF
    Publication number: 20160317527
    Abstract: The present application relates to use of compounds of formula I for treating or preventing a fibrosis.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 3, 2016
    Inventors: Ben C. Askew, D. Scott Edwards
  • FLUORINATED INTEGRIN ANTAGONISTS
    Publication number: 20160075698
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: February 7, 2014
    Publication date: March 17, 2016
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated 2-Amino-4-(Benzylamino)Phenylcarbamate Derivatives
    Publication number: 20150098902
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 9, 2015
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards, Ajay Purohit
  • Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
    Patent number: 8916133
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 23, 2014
    Assignee: SciFluor Life Sciences, LLC
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards, Ajay Purohit
  • Fluorinated 2-Amino-4-(Benzylamino)Phenylcarbamate Derivatives
    Publication number: 20130287686
    Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Applicant: SCIFLUOR LIFE SCIENCES, LLC
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards, Ajay Purohit
  • Fluorinated Benzofuran Derivatives
    Publication number: 20130274325
    Abstract: The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 17, 2013
    Inventors: Mark E. Duggan, Takeru Furuya, D. Scott Edwards
  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 7052673
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: May 30, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D Harris, Stuart D Heminway, Shuang Liu, Singh R Prahlad
  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 6800273
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: October 5, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh